These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 25127542

  • 1. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
    Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, Linari S, Perria C, Bembi B.
    Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
    [Abstract] [Full Text] [Related]

  • 2. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Nov; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 3. The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy.
    Sawicka-Gutaj N, Machaczka M, Kulińska-Niedziela I, Bernardczyk-Meller J, Gutaj P, Sowiński J, Ruchała M.
    Ups J Med Sci; 2016 Aug; 121(3):192-5. PubMed ID: 27064303
    [Abstract] [Full Text] [Related]

  • 4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 5. Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience.
    Gumus E, Karhan AN, Hizarcioglu-Gulsen H, Demir H, Ozen H, Saltik Temizel IN, Dokmeci Emre S, Yuce A.
    Eur J Med Genet; 2021 Nov; 64(11):104339. PubMed ID: 34500086
    [Abstract] [Full Text] [Related]

  • 6. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
    Grigorescu-Sido P, Drugan C, Alkhzouz C, Zimmermann A, Coldea C, Denes C, Grigorescu MD, Cret V, Bucerzan S.
    Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
    [Abstract] [Full Text] [Related]

  • 7. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
    El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK.
    J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874
    [Abstract] [Full Text] [Related]

  • 8. Hematopoietic stem cell transplantation or enzyme replacement therapy in Gaucher disease type 3.
    Høj A, Ørngreen MC, Naume MM, Lund AM.
    Mol Genet Metab; 2024 Aug; 142(4):108515. PubMed ID: 38909587
    [Abstract] [Full Text] [Related]

  • 9. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
    Ceravolo F, Grisolia M, Sestito S, Falvo F, Moricca MT, Concolino D.
    J Med Case Rep; 2017 Jan 20; 11(1):19. PubMed ID: 28103924
    [Abstract] [Full Text] [Related]

  • 10. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
    Lebel E, Elstein D, Peleg A, Reinus C, Zimran A, Amir G.
    Am J Clin Pathol; 2013 Jul 20; 140(1):91-6. PubMed ID: 23765538
    [Abstract] [Full Text] [Related]

  • 11. Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease.
    Donald A, Björkvall CK, Vellodi A, GAUCHERITE Consortium, Cox TM, Hughes D, Jones SA, Wynn R, Machaczka M.
    Orphanet J Rare Dis; 2022 Jun 18; 17(1):234. PubMed ID: 35717194
    [Abstract] [Full Text] [Related]

  • 12. Management of Gaucher disease: enzyme replacement therapy.
    Zimran A, Elstein D.
    Pediatr Endocrinol Rev; 2014 Sep 18; 12 Suppl 1():82-7. PubMed ID: 25345089
    [Abstract] [Full Text] [Related]

  • 13. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R, Arndt S, Levin JB.
    S Afr Med J; 2004 Aug 18; 94(8):647-51. PubMed ID: 15352589
    [Abstract] [Full Text] [Related]

  • 14. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease.
    Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R.
    J Pediatr; 2007 Aug 18; 151(2):197-201. PubMed ID: 17643778
    [Abstract] [Full Text] [Related]

  • 15. Cessation of enzyme replacement therapy in Gaucher disease.
    Grinzaid KA, Geller E, Hanna SL, Elsas LJ.
    Genet Med; 2002 Aug 18; 4(6):427-33. PubMed ID: 12509713
    [Abstract] [Full Text] [Related]

  • 16. Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.
    Choy FY, Zhang W, Shi HP, Zay A, Campbell T, Tang N, Ferreira P.
    Blood Cells Mol Dis; 2007 Aug 18; 38(3):287-93. PubMed ID: 17196853
    [Abstract] [Full Text] [Related]

  • 17. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
    van Dussen L, Hendriks EJ, Groener JE, Boot RG, Hollak CE, Aerts JM.
    J Inherit Metab Dis; 2014 Nov 18; 37(6):991-1001. PubMed ID: 24831585
    [Abstract] [Full Text] [Related]

  • 18. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb 18; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 19. Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings.
    Ramadža DP, Zekušić M, Žigman T, Škaričić A, Bogdanić A, Mustać G, Bošnjak-Nađ K, Ozretić D, Ohno K, Fumić K, Barić I.
    Eur J Paediatr Neurol; 2021 May 18; 32():66-72. PubMed ID: 33836415
    [Abstract] [Full Text] [Related]

  • 20. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 18; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.